1Cohen E.E,,Needles B.M,,Cullen K Jet al.Phase2study of sunitinib in refractory thyroid cancer[].Journal of Clinical Oncology.2008
2Mariani G,Cardoso F,Besse Hammer T,et al.Sequential administration of sunitinib(SU)and docetaxel(D)in women with advanced breast cancer(ABC):an exploratory evaluation[].Journal of Clinical Oncology.2008
3Saltz LB,,Rosen LS,Marshall JL,et al.Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy[].Journal of Clinical Oncology.2008
4Vigil C.E,,Chiappori A.A,,Williams C.A,et al.Phase II study of sunitinib malate(SM)in subjects with metastatic and/or surgically unresectable non.GIST soft tissue sarcomas[].Journal of Clinical Oncology.2008
5George D.J,,Liu G,Wilding G,et al.Sunitinib in combina.tion with docetaxel and prednisone in patients with metastatic hor.mone.refractory prostate cancer(mHRPC).preliminary re.sults[].Journal of Clinical Oncology.2008
6Grnwald V,Heinzer H,Fiedler W.Managing side effects of angiogenesis inhibitors in renal cell carcinoma[].Onkologie.2007
7M.A.Amantea,,B.E.Houk,,C.Bello,et al.Population phar.macokinetics of sunitinib in Japanese and Western healthy volun.teers,solid tumor,metastatic renal cell carcinoma(MRCC)and imatinib.resistant or.intolerant.gastrointestinal stromal tumors(GIST)patients[].Journal of Clinical Oncology.2008
8Washington C,Eli M,Bello C,et al.The effect of ketoconazole(KETO),a potent CYP3A4inhibitor,on SU011248pharmaco.kinetics(PK)in Caucasian and Asian healthy subjects[].Proceedings of the American Society of Clinical Oncology.2003
9Bello C,Houk B,Sherman S,et al.Effect of rifampin on the pharmacokinetics of SU011248in healthy volunteers[].J Clin Oncol.2005
10Figlin R.A,,Hutson T.E,,Tomczak P,et al.Overall survival with sunitinib versus interferon(IFN).alfa as first.line treat.ment of metastatic renal cell carcinoma(mRCC)[].Journal of Clinical Oncology.2008
